Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI-1910 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- BioInvent International
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BI-1910 + pembrolizumab is a combination therapy under investigation for the treatment of advanced or metastatic solid tumors whose disease has progressed after standard therapy. BI-1910 is a monoclonal antibody that targets Tumor Necrosis Factor Receptor 2 (TNFR2), modulating immune responses and potentially enhancing anti-tumor immunity. Pembrolizumab (brand name: Keytruda) is a monoclonal antibody that blocks the programmed death-1 (PD-1) receptor, thereby restoring T cell activity against tumors. The combination aims to utilize dual immune modulation by blocking inhibitory signals (PD-1) and targeting TNFR2-expressing regulatory cells within the tumor microenvironment.
- Other names
- pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TNFR2 (Tumor necrosis factor receptor superfamily member 1B)
Beyond the preview
Go deeper on BI-1910 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI-1910 + pembrolizumab.